COVID vaccination: LYSA recommendations
The LYSA totally recommends vaccination against Covid for patients with or having had lymphoma
Risk of serious complication following COVID infection in patients with lymphoma is greater than in the general population. Even if the data regarding patients with cancer of immunosuppression is limited, the benefice/risk balance is undoubtedly in favor of vaccination of these patients.
The vaccines approved by the authorities and marketed in Europe do not present any identified risk in immunocompromised patients. The only contraindication to vaccination is a severe allergy to a previous vaccination.
Depending on your treatment, your physician will be able to determine the best time for vaccination. Talk to him or her about it!
Moreover, the efficacy of vaccination against symptomatic forms of covid-19 is not 100% and protection against transmission of the virus is not currently known. It is therefore essential to continue to apply preventive measures, even after having been vaccinated.